Opendata, web and dolomites

TICARDIO SIGNED

Thrombo-inflammation in cardiovascular disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TICARDIO project word cloud

Explore the words cloud of the TICARDIO project. It provides you a very rough idea of what is the project "TICARDIO" about.

benefit    companies    generation    patient    disarrayed    vasculature    cvd    independently    strategic    heavy    risk    mechanisms    training    broadly    central    medical    becomes    competitive    multidisciplinary    multifaceted    exposing    basic    dissect    business    health    cardiovascular    killers    pathological    myocardial    demographic    care    settings    cell    complications    thrombosis    infarction    linkages    technologies    germany    serve    beneficiaries    setting    despite    diverse    age    complementary    stroke    minded    biomedical    medicine    pharmaceutical    company    creative    interplay    unravel    blueprint    thrombo    atherosclerosis    independent    completion    careers    small    populations    worldwide    disease    vascular    finely    outstanding    multicellular    aging    centres    academic    train    tuned    drivers    environment    burden    translate    fosters    alliance    integration    inflammation    successful    types    france    mechanistic    area    unmet    entrepreneurial    interconnected    ticardio    interactions    omics    translational    places    provides    netherlands    structures    knowledgeable    formed   

Project "TICARDIO" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ 

Organization address
address: Langenbeckstrasse 1
city: Mainz
postcode: 55131
website: http://www.um-mainz.de/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 3˙944˙037 €
 EC max contribution 3˙944˙037 € (100%)
 Programme 1. H2020-EU.1.3.1. (Fostering new skills by means of excellent initial training of researchers)
 Code Call H2020-MSCA-ITN-2018
 Funding Scheme MSCA-ITN-EJD
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2023-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ DE (Mainz) coordinator 1˙263˙942.00
2    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 1˙328˙099.00
3    UNIVERSITE D'AIX MARSEILLE FR (Marseille) participant 1˙099˙208.00
4    LEIBNIZ-INSTITUT FUR ANALYTISCHE WISSENSCHAFTEN-ISAS-EV DE (DORTMUND) participant 252˙788.00
5    2M ENGINEERING LIMITED UK (FOLKSTONE) partner 0.00
6    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) partner 0.00
7    Biocytex FR (MARSEILLE) partner 0.00
8    BOEHRINGER INGELHEIM PHARMA GMBH &CO KG DE (INGELHEIM) partner 0.00
9    TRON - TRANSLATIONALE ONKOLOGIE ANDER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH DE (MAINZ) partner 0.00
10    TTOPSTART BV NL (UTRECHT) partner 0.00

Map

 Project objective

The demographic change with aging populations places a heavy burden on health care systems worldwide. Despite all medical advances, age remains the major risk for cardiovascular disease (CVD), one of the top two killers. The aging vasculature provides an environment in which the finely tuned interplay between diverse cell types becomes disarrayed and thus fosters both, inflammation and thrombosis. For atherosclerosis and major vascular complications, i.e. myocardial infarction and stroke, inflammation and thrombosis are central pathological processes that have commonly been investigated independently, but now need integration within the new concept of 'vascular thrombo-inflammation'. Four beneficiaries have formed a strategic alliance to unravel the multifaceted mechanisms involved in thrombo-inflammation in the setting of CVD and identified interconnected research projects that benefit from the collaboration between outstanding centres in France, Germany and The Netherlands. Using unique and complementary advanced technologies, TICARDIO will dissect the mechanistic linkages between inflammation and thrombosis, investigate the multicellular interactions in the vasculature as drivers for thrombo-inflammation, and translate new concepts by multi-omics approaches into patient populations. The programme will train the next generation of basic and translational researchers by exposing them to a multidisciplinary research environment at major academic centres and a range of entrepreneurial and business settings at small and large pharmaceutical companies in Europe. The completion of an independent project in a research area with high unmet medical need will foster the development of creative, open minded and broadly knowledgeable biomedical researchers who are competitive for successful academic and company careers all over Europe. TICARDIO’s structures and interactions will serve as a blueprint for future training programmes in emerging fields of cardiovascular medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TICARDIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TICARDIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.1.)

ORBITAL (2019)

Ocular Research By Integrated Training And Learning

Read More  

HeatNMof (2020)

Heating triggered drug release from nanometric inorganic-metal organic framework composites

Read More  

INSPIRE (2020)

INnovation in Safety Pharmacology for Integrated cardiovascular safety assessment to REduce adverse events and late stage drug attrition.

Read More